Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $30.7M | $31.8M | $29.9M | $31.6M | $23.1M | $30.0M | $36.2M | $33.4M | $33.6M | $30.7M |
| Revenue growth | — | 3.4% | -6.0% | 5.8% | -26.9% | 29.8% | 20.6% | -7.8% | 0.6% | -8.5% |
| Gross profit | $18.1M | $18.8M | $17.1M | $20.3M | $14.1M | $19.9M | $21.8M | $18.5M | $19.2M | $17.9M |
| Gross margin | 58.8% | 59.1% | 57.3% | 64.2% | 61.2% | 66.2% | 60.2% | 55.3% | 57.3% | 58.3% |
| Operating income | -$3.60M | -$1.80M | -$3.35M | -$3.01M | -$4.08M | -$4.40M | -$4.65M | -$8.60M | -$9.26M | -$4.70M |
| Operating margin | -11.7% | -5.7% | -11.2% | -9.5% | -17.7% | -14.7% | -12.9% | -25.8% | -27.6% | -15.3% |
| Net income | -$3.33M | -$21.5M | -$4.03M | -$3.79M | -$4.41M | -$2.71M | -$5.55M | -$10.8M | -$10.1M | -$6.26M |
| Net margin | -10.9% | -67.7% | -13.5% | -12.0% | -19.1% | -9.0% | -15.3% | -32.5% | -30.1% | -20.4% |
| EPS (diluted) | -$3.77 | -$3.26 | -$0.15 | -$0.11 | -$0.13 | — | -$0.16 | -$3.10 | -$2.65 | -$1.35 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $322K | $4.14M | $2.90M | $2.23M | $2.10M | $1.51M | -$924K | -$519K | $188K | -$2.79M |
| Capital expenditures | — | — | — | $115K | $2.16M | $3.65M | $3.74M | $5.02M | $1.64M | $1.47M |
| Free cash flow | — | — | — | $2.11M | -$63.0K | -$2.15M | -$4.66M | -$5.54M | -$1.45M | -$4.26M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $3.93M | $3.76M | $16.5M | $8.13M | $10.6M | $12.6M | $5.43M | $6.78M | $7.26M | $7.91M |
| Total assets | $43.2M | $43.2M | $47.5M | $47.3M | $46.8M | $46.6M | $52.3M | $42.0M | $39.2M | $33.0M |
| Total liabilities | $28.2M | $32.0M | $16.3M | $18.7M | $20.9M | $21.2M | $30.4M | $29.3M | $29.8M | $30.1M |
| Long-term debt | $9.75M | $8.95M | $7.14M | $0.00 | $1.05M | $7.32M | $7.48M | $15.0M | $15.2M | $0.00 |
| Shareholders' equity | $15.0M | $19.9M | $31.2M | $28.7M | $25.9M | $25.4M | $21.8M | $12.7M | $9.43M | $2.98M |
| Retained earnings | -$182M | -$186M | -$211M | -$215M | -$219M | -$222M | -$227M | -$238M | -$241M | -$250M |
| Shares (wtd avg diluted) | 2.32M | 2.71M | 19.6M | 32.0M | 33.6M | 34.4M | 34.7M | 3.49M | 3.81M | 4.65M |
Every figure is extracted from STRATA Skin Sciences, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.